BioSpace News Archive

For the third time this year, Clarify Health, a leading healthcare analytics platform company, is being honored by Frost & Sullivan.

INVO Bioscience, Inc. announced the birth of the first baby in Malaysia utilizing the INVOcell solution.

Eliem Therapeutics, Inc. today announced that Bob Azelby, Eliem’s president and chief executive officer, will present at the 5th Annual Evercore ISI HealthCONx Virtual Conference being held virtually on Thursday, December 1, 2022 at 11:40 AM ET.

Pulmonx Corporation announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr ® Endobronchial Valve for treating severe COPD/emphysema patients.

Corner Therapeutics today announced three presentations of data on its dendritic cell hyperactivation (hDC) platform at the 4th Inflammasome Therapeutics Summit, taking place November 29 to December 1, 2022 in Boston, Massachusetts.

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $102 million.

Promontory Therapeutics Inc. will present clinical data on lead therapeutic candidate, PT-112, in combination with avelumab, and its immunogenic cell death inducing effects in patients with advanced non-small cell lung cancer as a poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2022 in Geneva, Switzerland, on Dec. 7-9.

Clarametyx Biosciences Inc . today announced the initiation of its clinical development program for CMTX-101, a novel immune-enabling antibody therapy designed to treat serious bacterial infections.

Nectin Therapeutics Ltd announced today dosing of the first patient in its Phase 1 clinical trial of NTX1088, Nectin’s first-in-class PVR (CD155) blocker, in cancer patients with locally advanced and metastatic solid tumors.

TIANGENhas announced its participation in the Cell Bio 2022, the joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), from December 4 to 6, in Washington, DC.